China’s rapidly expanding role in global pharmaceutical innovation is opening new avenues for Pakistan to pursue technology transfer, joint research, and local manufacturing partnerships. Official data show that innovative-drug out-licensing deals in China reached about $110 billion in the first half of 2026 through 81 transactions, signaling a surge in cross-border life-sciences cooperation that could help Pakistan build domestic capabilities rather than remain heavily dependent on imported pharmaceutical technologies and inputs.
Global Growth in Chinese Pharmaceutical Innovation
The opportunity for international collaboration has gained momentum as Chinese-developed drugs attract growing global interest. Official Chinese data show that out-licensing deals in the first half of 2026 reached about $110 billion across 81 transactions, hitting roughly 80% of the total value recorded during all of 2025. Spanning about 20 countries and regions, these deals involved 10 therapeutic areas, such as neurological, immune, metabolic, and oncology diseases.
According to China’s National Medical Products Administration, the country accounted for about 30% of new drugs under development globally. The number of clinical trials conducted in China surpassed 5,000 for the first time in 2025, with 2,997—or 57.5%—involving new drugs. This followed a strong 2025 in which China approved 76 innovative drugs, up from 48 in 2024, alongside more than 150 overseas licensing transactions exceeding $130 billion in potential value.
Bilateral Engagements and Commercial Agreements
Recent engagements indicate that cooperation between Pakistan and China in the pharmaceutical sector is already translating into commercial projects. According to the Ministry of National Health Services, 22 commercial agreements totaling $629.5 million resulted from a Pakistan-China pharmaceutical conference conducted in Islamabad during July. The event also yielded 84 memoranda of understanding with an estimated value of around $800 million.
That conference brought together 240 Chinese delegates representing 140 companies alongside 430 Pakistani representatives from 210 local firms. The resulting commercial agreements targeted active pharmaceutical ingredients (APIs), local vaccine production, clinical trials, generic formulations, injectables, and medical-device manufacturing. Previously, in May 2026, firms from China and Pakistan entered into 10 MoUs regarding pharmaceutical investment, vaccine collaboration, technology transfer, and API manufacturing.
Addressing Domestic Dependence and Manufacturing Gaps
The push for technology transfer is vital for Pakistan’s domestic market structure. According to the Ministry of National Health Services, Pakistan currently produces nearly 85% of its pharmaceutical products domestically but still imports about 95% of the raw materials used in medicine manufacturing. Expanding cooperation in APIs, vaccines, biotechnology, and manufacturing could help the country increase local value addition and develop the technical capabilities required for sophisticated production.
This industrial pivot coincides with a broader push for international reach. According to the Finance Division, Pakistan’s pharmaceutical exports registered a record 34% year-on-year increase in 2025, prompting the industry to propose a dedicated PharmEx Pakistan platform to support market diversification, international certification, and export expansion.
Expert Insights on Technology Absorption and Localisation
Building stronger university-industry linkages, joint research programmes, clinical-research capacity, and mechanisms for absorbing transferred technology are essential for Pakistan to develop its own innovation capabilities, experts note. Dr Muhammad Saalim, Assistant Professor at the Capital University of Science & Technology (CUST) in Islamabad and R&D Consultant at PsiMega2 (Pvt.) Ltd., a biotechnology R&D and contract research organisation, pointed to China’s model of academic-industrial collaboration.
“From my experience of studying and working in China, I believe a major strength is the close collaboration between academia and industry, allowing China to address both current and future challenges,” Saalim said in an interview with Wealth Pakistan. He identified technology transfer, capacity building, and joint research as the most promising areas for cooperation.
“Rather than simply importing finished technologies, Pakistan could learn from China’s approach of acquiring, localising, adapting and further developing technologies,” Saalim said, comparing the potential life-sciences strategy to China’s high-speed rail development as an example of broader technological absorption.
Outlook and Future Cooperation Pathways
As bilateral ties deepen, the longer-term opportunity for Pakistan may extend far beyond attracting Chinese factories or importing newly developed medicines. Experts suggest that utilising these partnerships could help the country move progressively away from dependence on imported inputs and technologies. By focusing on local research, technology absorption, and advanced manufacturing, Pakistan could secure greater participation in the global life-sciences value chain.
Keep reading